Steve Pakola Sells 15,309 Shares of REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 15,309 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $11.02, for a total transaction of $168,705.18. Following the transaction, the insider directly owned 232,617 shares in the company, valued at $2,563,439.34. The trade was a 6.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Steve Pakola also recently made the following trade(s):

• On Tuesday, March 10th, Steve Pakola sold 5,124 shares of REGENXBIO stock. The stock was sold at an average price of $10.35, for a total transaction of $53,033.40.

REGENXBIO Stock Performance

REGENXBIO stock traded down $0.20 during midday trading on Wednesday, hitting $10.04. 1,800,523 shares of the company’s stock were exchanged, compared to its average volume of 910,122. REGENXBIO Inc. has a 12-month low of $7.35 and a 12-month high of $16.19. The stock has a market cap of $518.26 million, a price-to-earnings ratio of -2.67 and a beta of 1.12. The firm’s 50 day simple moving average is $8.96 and its 200 day simple moving average is $11.10.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.29). REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.The firm had revenue of $30.34 million during the quarter, compared to analyst estimates of $45.48 million. On average, equities research analysts forecast that REGENXBIO Inc. will post -2.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. UBS Group restated an “overweight” rating and issued a $18.00 target price on shares of REGENXBIO in a research note on Tuesday, February 10th. HC Wainwright reduced their target price on shares of REGENXBIO from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Robert W. Baird set a $27.00 target price on shares of REGENXBIO in a research note on Tuesday, February 10th. Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Finally, Barclays initiated coverage on shares of REGENXBIO in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.50.

Hedge Funds Weigh In On REGENXBIO

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp raised its position in shares of REGENXBIO by 44.4% in the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 1,270 shares in the last quarter. Profund Advisors LLC increased its stake in shares of REGENXBIO by 11.8% in the third quarter. Profund Advisors LLC now owns 14,444 shares of the biotechnology company’s stock worth $139,000 after buying an additional 1,523 shares during the last quarter. Deutsche Bank AG increased its stake in shares of REGENXBIO by 0.8% in the fourth quarter. Deutsche Bank AG now owns 192,582 shares of the biotechnology company’s stock worth $2,773,000 after buying an additional 1,527 shares during the last quarter. Captrust Financial Advisors boosted its stake in REGENXBIO by 13.2% during the 4th quarter. Captrust Financial Advisors now owns 15,228 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 1,781 shares during the last quarter. Finally, Diversified Trust Co boosted its stake in REGENXBIO by 15.9% during the 1st quarter. Diversified Trust Co now owns 15,499 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 2,121 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.